The concern of generic challenges has consistently loomed over copyright’s famous drug, Sildenafil, triggering questions about the future of similar pharmaceutical ventures. While first times saw impressive profits, the intellectual property end has created the way for cheaper alternatives, potentially lowering earnings and posing a real risk for